Trialist
Satisfied with current toxins and can manage the high numbers of patients See most days. Use all toxins but choose the one that is available at the time and easy to use.
Use Dysport® more frequently. Believe it can help him run their clinic more efficiently and it tends to lead to lower symptom recurrence cycle after cycle.
A.Demonstrate efficiency and clinic benefits of using Dysport®
Emphasize accessibility of HCP support to simplify patient and clinic management
Demonstrate Dysport® benefits and applicability across patient types
Messaging should be straight to the point, without complexity, with a focus on practical aspects of using Dysport®.
Communication objective associated: Emphasize accessibility of HCP support to simplify patient and clinic management
More patients can access treatment thanks to Dysport®’s broad reimbursement coverage in spasticity. This extensive access enables clinicians to treat a wider spectrum of patients without administrative barriers
Broad reimbursement ensures timely initiation and sustained treatment, helping patients achieve functional goals and maintain independence
Key supportive reference:
RIZIV/INAMI :
Key material:
Digital material for follow up:
Communication objective associated: Demonstrate Dysport® benefits and applicability across patient types
Dysport® could provide sustained benefits in daily life, specifically in everyday tasks that involve carrying, reaching, grasping and releasing
Dysport® helps enable patients to walk faster, giving them the confidence to maintain their independence
Real-world studies show these improvements happen consistently, cycle after cycle, in routine practice.
Key supportive study :
Key material:
Digital material for follow up:
Communication objective associated: Demonstrate efficiency and clinic benefits of using Dysport®
Dysport® is proven to deliver sustained symptom control in phase 3 clinical trials
Dysport® demonstrated longer-lasting symptom control vs other BoNT-As in routine clinical practice in upper limb spasticity
Longer intervals between injections mean fewer appointments and lower overall treatment costs.
Main key supportive study :
Key material:
Digital material for follow up:
Communication objective associated: Demonstrate efficiency and clinic benefits of using Dysport®
Dysport® contains more active neurotoxin within the licensed maximum dose than any other avaible BoNT-A
62% of patients responded to Dysport® when the upper limb was their primary treatment target; 83% for lower limb.
Recommended doses for upper / lower limb muscles
Dysport® has a dose-response effect
Main key supportive study :
Key material:
Digital material for follow up:
Communication objective associated: Demonstrate efficiency and clinic benefits of using Dysport®
Main key supportive study :
Key material:
Communication objective associated: Emphasize accessibility of HCP support to simplify patient and clinic management
Key material
Digital material for follow up